lasofoxifene has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lawson, S; Ouyang, P; Valdiviezo, C | 1 |
| de Villiers, TJ | 1 |
| Hamilton, CJ; Jamal, SA; Swan, VJ | 1 |
3 review(s) available for lasofoxifene and Cardiovascular Diseases
| Article | Year |
|---|---|
An update on menopausal hormone replacement therapy in women and cardiovascular disease.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Stroke; Tetrahydronaphthalenes; Time Factors; United States; Venous Thrombosis; Women's Health | 2013 |
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2009 |
Lasofoxifene in osteoporosis and its place in therapy.
Topics: Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Female; Humans; Middle Aged; Musculoskeletal Diseases; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Women's Health | 2010 |